Previous 10 | Next 10 |
Royalty Pharma ( RPRX ) went public in June as I concluded that the company is an interesting business and stock to follow. I noted that the company has seen steady growth, is very profitable, leverage is modest, pro-forma earnings multiples look compelling, and on top of that, the company...
Royalty Pharma plc (RPRX) Q2 2020 Earnings Conference Call August 12, 2020 08:00 AM ET Company Participants George Grofik - Senior Vice President, Head of Investor Relations & Communications Pablo Legorreta - Founder & Chief Executive Officer Marshall Urist - Senior Vice ...
The following slide deck was published by Royalty Pharma plc in conjunction with their 2020 Q2 earnings Read more ...
Royalty Pharma (NASDAQ: RPRX ) : Q2 net income of 442M More news on: Royalty Pharma plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Strong double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts (1) (non-GAAP) Company introduces 2020 guidance: Adjusted Cash Receipts expected to be $1,720 to $1,760 million $1.7 billion of new acquisitions announced in 20...
- Biohaven will receive up to $250 million to fund zavegepant’s development in migraine and non-migraine indications - Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of Nurtec™ ODT and success-based milestone payments - Royalty Pharma ...
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced the appointments of Henry A. Fernandez and Ted W. Love, M.D. to the company's Board of Directors, effective immediately. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc., a leading gl...
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (NASDAQ: RPRX) today announced that it will report its second quarter 2020 financial results on Wednesday, August 12, 2020, before the U.S. financial markets open. The Company will host a conference call and simultaneous ...
Royalty Pharma (NASDAQ: RPRX ) is purchasing ~43% of the royalty up to a specified amount. More news on: Royalty Pharma plc, PTC Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty interest in risdiplam for a one-time payment of $650 million. Risdiplam, to be marketed by Ro...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...